The Deceptive Simplicity of "Does It Work?"

The history of clinical trials is not a linear march toward perfection, but a messy, centuries-long struggle against human bias and the inherent complexities of medicine. This conversation reveals that the seemingly straightforward question of "how do we know if a treatment works?" is deeply intertwined with human nature, economic realities, and evolving ethical considerations. Anyone involved in healthcare, research, or even simply making informed decisions about their own well-being will gain an advantage by understanding the non-obvious implications of how we test treatments. This isn't just about scientific rigor; it's about recognizing the deep-seated human tendencies that have shaped, and continue to shape, medical progress.

The Deceptive Simplicity of "Does It Work?"

The journey to understanding whether a medical treatment truly works is far more convoluted than it appears. What seems like a simple question -- does this drug or procedure alleviate suffering and improve health? -- has taken centuries to even begin to answer reliably. The core challenge, as illuminated by this discussion, is not just the biological complexity of the human body, but the pervasive influence of human bias. From the earliest "trick trials" of the 16th century, where fake exorcisms were used to test the efficacy of genuine religious rites, to the sophisticated randomized controlled trials (RCTs) of today, the fundamental problem remains: how do we isolate the true effect of an intervention from the myriad other factors at play, including the patient's belief, the researcher's hopes, and the economic pressures of drug development?

This struggle is vividly illustrated by the early attempts to understand mesmerism. In the 1760s and 1770s, when mesmerism was popular, the French Academy of Science, with luminaries like Benjamin Franklin involved, conducted trials comparing real mesmerism to sham mesmerism. The subjects were blinded to whether they were receiving the "real" treatment. The conclusion? Sham mesmerism was as effective as actual mesmerism, suggesting neither had a genuine therapeutic effect beyond the psychological. This early experiment highlights a recurring theme: the power of the placebo effect and the difficulty of disentangling it from the actual treatment.

"The conclusion was the sham mesmerism was just as effective as actual mesmerism."

-- Transcript

The evolution from these early, flawed experiments to modern RCTs is a testament to the iterative nature of scientific progress, driven by the recognition of successive layers of bias. The introduction of single-blind studies, where only the patient is unaware of their treatment allocation, was an improvement. However, the realization that researchers themselves could be biased -- consciously or unconsciously -- led to the development of double-blind studies. Here, neither the patient nor the evaluator knows who is receiving the treatment and who is receiving the placebo. This was a critical step in ensuring that observations and evaluations were not skewed by preconceived notions of a treatment's efficacy.

But even double-blinding doesn't solve everything. The method of allocating participants to treatment or control groups proved to be another fertile ground for bias. Early methods like alternate allocation, where every other person received the treatment, were found to be unreliable, with researchers subconsciously (or consciously) steering participants to maximize perceived positive outcomes for the treatment group. This led to the development of randomization, a cornerstone of modern RCTs, where participants are assigned to groups by chance.

"The problem runs deeper: researchers would you know put the younger healthier people into the experimental arm and they'll put the older sicker person into the control arm and sure enough the younger healthier people will have a better outcome and they'd falsely conclude that the drug worked."

-- Transcript

The development of randomization, championed by figures like Austin Bradford Hill, marked a significant leap forward. By using random numbers to determine treatment allocation, the goal was to create groups that were as statistically similar as possible, thus isolating the effect of the treatment itself. This rigorous process, designed to overcome "human foibles," has become the gold standard for pharmaceutical trials.

The Uncomfortable Truths of the Gold Standard

While RCTs are indispensable, the conversation reveals that even this gold standard is not without its limitations and controversies. One fundamental critique is that RCTs focus on group averages, which may not accurately reflect the experience of an individual patient. The analogy of a shoemaker designing a shoe for the "average" foot, which would fit no one perfectly, illustrates this concern. While medicine is more complex than shoes, the principle remains: an average outcome doesn't guarantee individual success.

Furthermore, the sheer cost and time involved in conducting RCTs raise practical questions. With trials costing millions of dollars, the question arises: does every treatment truly warrant such an extensive investigation? The examples of penicillin, appendectomies, and parachutes are often cited to argue that some interventions are so obviously effective that rigorous trials seem redundant. However, the discussion wisely pushes back on this, using the example of appendectomies. For decades, immediate surgery was the standard, but later research showed that antibiotics could be a viable first-line treatment for many patients, demonstrating that even seemingly obvious interventions can benefit from rigorous testing.

The ethical landscape of clinical trials is another area where the conversation highlights significant downstream complexities. The historical exploitation of vulnerable populations, such as prisoners and individuals in developing countries with limited access to healthcare, underscores the constant need for vigilance. The practice of using "treatment-naive" subjects in impoverished regions for expensive treatments that will never be available there raises profound ethical dilemmas, even if the research itself is scientifically sound. This points to a crucial systemic issue: the tension between the need for robust data and the ethical imperative to ensure equitable access and avoid exploitation.

Surgery's Slippery Slope: Bias in the Operating Room

The application of RCTs to surgical techniques presents unique challenges that reveal deeper systemic issues. Unlike pharmaceuticals, where a pill is a pill, surgical skill varies dramatically between practitioners. This variation makes it difficult to conduct truly double-blind RCTs. When a trial shows a surgical technique to be ineffective, critics can easily dismiss the results by arguing that the surgeons involved were simply not skilled enough.

"The surgeons and patients have their own biases and we want to make sure we remove these biases when evaluating how well a given surgery works but as David told us there are actually some aspects of surgery that make it quite distinct from testing out a drug for one unlike handing a patient a drug there's a lot more variation in how surgeons apply their skill."

-- Transcript

This dynamic plays out in institutions, where elite surgeons in private centers may criticize trials conducted by surgeons in less prestigious settings like the VA system. The argument that the "average" patient isn't treated by an elite surgeon, but by a typical community surgeon, suggests that RCTs might, in fact, be the most appropriate venue for evaluating surgical outcomes in real-world conditions, even if they are not perfectly blinded. The development of "sham surgeries," where control groups undergo a procedure that mimics the real surgery without the actual therapeutic intervention, is a fascinating, albeit ethically complex, attempt to bring blinding to surgical research. This innovation, particularly in orthopedic surgery, demonstrates a commitment to uncovering the true efficacy of procedures, even when it requires significant ingenuity and careful ethical navigation.

The Long Game: Delayed Payoffs and Enduring Principles

Ultimately, the history and ongoing evolution of clinical trials underscore a critical principle: true progress often involves delayed payoffs and requires a willingness to confront uncomfortable truths. The pursuit of scientific rigor is a continuous process of identifying and mitigating human biases, from the individual patient to the global research enterprise. While RCTs are a powerful tool, their limitations and the ethical considerations surrounding them are just as important as their strengths. The conversation reveals that the scientific method, with its inherent self-correcting mechanisms, is not about achieving perfection, but about making continuous progress in the face of uncertainty and human fallibility.

Key Action Items

• Immediate Action (Next Quarter): Familiarize yourself with the concept of blinding (single vs. double) and randomization in clinical trials. Understand why these elements are crucial for mitigating bias.
• Immediate Action (Next Quarter): Critically evaluate health information you encounter, asking whether the evidence presented is based on robust clinical trials or anecdotal reports.
• Short-Term Investment (3-6 Months): When considering medical treatments, inquire about the evidence base. Ask your healthcare provider if the treatment is supported by randomized controlled trials and what the known side effects are.
• Short-Term Investment (3-6 Months): For those in research or development, actively seek out training on ethical considerations in clinical trial design, particularly concerning informed consent and the use of vulnerable populations.
• Mid-Term Investment (6-12 Months): Advocate for transparency in clinical trial reporting, supporting initiatives that make trial data and methodologies publicly accessible.
• Long-Term Investment (12-18 Months): Support or engage with organizations that are working to improve the accessibility and ethical conduct of clinical trials globally, ensuring that research benefits all populations.
• Ongoing Practice (Now and Always): Recognize that medical "wisdom" can evolve. Be open to new evidence, even if it challenges long-held beliefs or established practices, much like the shift in appendicitis treatment. This discomfort now creates an advantage of better health outcomes later.